OraSure Technologies, Inc. (FRA:EP3)

Market Cap	179.99M -13.5%
Revenue (ttm)	97.96M -38.1%
Net Income	-58.54M
EPS	-0.80
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	2.600
Previous Close	2.580
Day's Range	2.520 - 2.600
52-Week Range	1.800 - 3.040
Beta	n/a
RSI	47.26
Earnings Date	May 6, 2026

About OraSure Technologies

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid tes...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 1987
• Employees: 500
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EP3

Financial Performance

In 2025, OraSure Technologies's revenue was $115.02 million, a decrease of -38.10% compared to the previous year's $185.83 million. Losses were -$68.73 million, 252.5% more than in 2024.

Financial numbers in USD